Compare
Amgen vs Exelixis (AMGN vs EXEL)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Amgen (AMGN) returned +43.9% and Exelixis (EXEL) +72.3%; so far this year the figures are +40.7% and +58.7%.
Amgen is the larger company by market value, about 14.7 times the size of Exelixis.
On trailing earnings, AMGN trades at 26.7 times and EXEL at 20.8 times.
Revenue grew +8.2% at AMGN and +9.1% at EXEL over the last year.
AMGN yields 2.16%. EXEL pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| AMGN | EXEL | |
|---|---|---|
| Price | $460.42 | $69.57 |
| 1-day | +0.03% | +1.25% |
| YTD | +40.67% | +58.73% |
| 1 year | +43.94% | +72.33% |
| 3 years | +76.51% | +230.97% |
| Market cap | $249.1B | $17.0B |
| P/E | 26.7 | 20.8 |
| P/S | 6.40 | 6.80 |
| P/B | 17.35 | 9.26 |
| Revenue growth | +8.20% | +9.10% |
| EPS growth | +33.30% | +40.90% |
| Gross margin % | 70.9 | 96.3 |
| Net margin % | 24.1 | 35.5 |
| ROE % | 65.4 | 48.3 |
| Debt / equity | 3.76 | 0.10 |
| FCF yield % | 3.8 | 6.8 |
| Dividend yield % | 2.16 | — |
| Beta | 0.50 | 0.61 |
| RSI (14) | 60.5 | 66.0 |
| Technical rating |